# Zeposia (ozanimod hydrochloride) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ozanimod

> The FDA approved Zeposia (ozanimod hydrochloride), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on March 25, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Zeposia (ozanimod hydrochloride) |
| Codes | RPC-1063 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Multiple Sclerosis](https://sec-api.dev/indications/multiple-sclerosis), [Colitis, Ulcerative](https://sec-api.dev/indications/colitis-ulcerative) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### March 25, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209899 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200325, review_priority STANDARD; sponsor_name BRISTOL; product ZEPOSIA (OZANIMOD HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209899%22

### May 27, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209899 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20210527, review_priority PRIORITY; sponsor_name BRISTOL; product ZEPOSIA (OZANIMOD HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209899%22

### August 30, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209899 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240830, review_priority STANDARD; sponsor_name BRISTOL; product ZEPOSIA (OZANIMOD HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209899%22

### May 15, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04140305 (Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04140305

### September 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03915769 (To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT03915769

## Same indication

- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Guselkumab subcutaneous](https://sec-api.dev/pdufa/guselkumab-subcutaneous) (JNJ)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838) (IMUX)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [LY4395089](https://sec-api.dev/pdufa/ly4395089) (LLY)
- [MRNA-1195](https://sec-api.dev/pdufa/mrna-1195) (MRNA)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Aubagio (teriflunomide)](https://sec-api.dev/pdufa/teriflunomide) (SNY)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [Ustekinumab dose based on bsa and body weight](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) (JNJ)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ozanimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zeposia (ozanimod hydrochloride) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ozanimod

```bibtex
@misc{secapidev_pdufa_ozanimod_20261116,
  title        = {Zeposia (ozanimod hydrochloride) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ozanimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ozanimod_20261116","title":"Zeposia (ozanimod hydrochloride) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ozanimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
